The exogenous administration of MaR1 (1 ng/mouse) to experimental animals during the allergic phase of asthma results in the decrease in eosinophils number in bronchoalveolar lavage, IgE, IL-5 and IL-13 levels and the increase in TGF-β concentration. This evidence concerns the gene IL13 and asthma.